On January 23, 2023 Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen’s leadership in the DNAM-1 axis (Press release, Compugen, JAN 23, 2023, View Source;tigit-landscape-overview-301727997.html [SID1234626470]). The fireside chat will take place on Monday, January 30, 2023, at 11:00 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.